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Time-Series Transcriptional Profiling Yields New Perspectives
on Susceptibility to Murine Osteoarthritis
Blandine Poulet,1 Veronica Ulici,2 Timothy C. Stone,1 Matthew Pead,1
Valentina Gburcik,1 Eleni Constantinou,1 Donald B. Palmer,1
Frank Beier,2 James A. Timmons,1 Andrew A. Pitsillides1
Results. We found that the OA in STR/Ort mice
exhibited a molecular phenotype resembling human
OA, and we pinpointed a central role of NF-B signaling
and the emergence of an immune-related signature in
OA cartilage over time. We discovered that, strikingly,
young healthy AC has a highly expressed skeletal muscle gene expression program, which is switched off
during maturation, but is intriguingly retained in AC
during OA development in STR/Ort mice.
Conclusion. This study is the first to show that AC
chondrocytes share a high-abundance gene-expression
program with skeletal muscle. We show that failure to
switch this program off, as well as the restoration of
this program, is associated with inappropriate expression of NF-B signaling pathways, skeletal muscle–
related genes, and induction and/or progression of OA.

Objective. Chronological age is a powerful epidemiologic risk factor for osteoarthritis (OA), a multifactorial disease that is characterized by articular cartilage (AC) degradation. It is unclear from a molecular
perspective how aging interacts with OA to produce this
risk to AC integrity. To address this key question, we
used in vivo time-course analysis of OA development
and murine interstrain variability in natural susceptibility to OA to examine changes in non–OA-prone CBA
mice versus OA-prone STR/Ort mice, which develop
disease that bears significant histologic resemblance to
human OA. Through global transcriptome profiling, we
attempted to discover the molecular signature linked
with both OA vulnerability and progression.
Methods. Affymetrix Mouse Gene 1.0 ST Array
profiles were generated from AC samples derived from
CBA and STR/Ort mice at 3 different ages, corresponding to the stages prior to, at, and late after the natural
onset of OA in the STR/Ort mice.

Osteoarthritis (OA) is a complex age-related,
multifactorial, polygenic disease characterized by degradation and consequent loss of the extracellular matrix
(ECM) of the articular cartilage (AC) (1). Chondrocytes, the only resident cells of AC, are vital for maintaining the integrity of normal joints, but they also
contribute to the initiation and progression of the loss of
AC in OA (2,3). These dual roles in healthy ECM
remodeling and in pathologic changes in the AC have
made it difficult to identify targets by which to limit OA
development or protect against increased susceptibility
during aging.
The study of OA currently relies upon in vivo
animal models, partly because it is difficult to obtain AC
samples during specific stages of OA in humans, as well
as healthy site- and age-matched samples for comparison. Preclinical models of OA are also needed for drug
development (4). Alternative comparative approaches
in humans have relied mostly upon using normal AC
samples and samples obtained during late-stage OA or
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samples taken from various proximities to OA lesions
(5). This has meant that specific factors that are crucial
in determining OA development remain unidentified.
This challenge is exacerbated by a lack of AC samples
obtained before the onset of OA from individuals with
known susceptibility to the disease.
It is therefore necessary to use models in which
OA susceptibility and time course are defined in order
to identify the predisposing and etiologic factors that
lead to OA. We and other investigators (6,7) have previously used gene array analysis of AC after OA induction in surgical models of the disease to identify
potential disease regulators. It is apparent that although
relevant to posttraumatic OA, such models do not necessarily mirror natural primary OA and responses to
surgery may complicate the analysis and results. Moreover, these models are not necessarily useful for identifying genes that predispose joints to the development of
OA, but rather, those that are involved in AC remodeling and pathology.
Different mouse strains exhibit distinct agerelated OA vulnerability (8). The inbred STR/Ort mouse
strain develops histologic OA spontaneously. Genetic
and microarray analyses and studies into the roles of
obesity, patellar dislocation, matrix metalloproteases
(MMPs), and inflammatory cytokines have yet to define
the cause of OA in STR/Ort mice. Their OA develops
over a relatively predictable time course, closely resembling primary OA in humans, with characteristic AC
proteoglycan loss and active ECM degradation by MMPs,
and likely involves genetic and mechanical factors (9–
11). In contrast, CBA mice show very low levels of OA
with age (9) and therefore represent a model of healthy
AC aging.
In the present study, we used AC from both
strains of mice, at ages corresponding to time points
before, at, and after the overt development of OA in
STR/Ort mice, to address whether specific AC gene
expression patterns characterize OA risk. Our primary
hypothesis was that differential gene expression prior to
disease onset would identify molecular markers of OA
risk. Second, we hypothesized that age-related changes
specific to OA-prone AC would pinpoint a molecular
program that contributes to OA progression. This would
provide new candidate genes for future studies that
attempt to discover, using targeted genetics (12), why
aging interacts with AC to produce OA risk in humans.
We contrasted the transcription profiles of chondrocytes
during normal AC aging (CBA mice) and during OA
(STR/Ort mice). We robustly demonstrated that normal
healthy AC has a signature characterized by an age-
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related decline in the transcription of a muscle-selective
gene repertoire, which is lacking in AC that is prone to
OA. The importance of NF-B pathway signaling in OA
development in a mouse model of naturally occurring
disease is highlighted.
MATERIALS AND METHODS
Animals and sample collection. Male CBA (Charles
River) and STR/Ort (bred in-house) mice were kept in polypropylene cages, at a temperature of 21°C (⫾2°C), with
12-hour light/dark cycles, and were fed standard RM1 maintenance diet ad libitum. All procedures complied with the
Animals (Scientific Procedures) Act 1986 and with guidelines
of the local ethics committee. Mice were used in experiments
at ages 8–10 weeks (young; 5 CBA and 6 STR/Ort mice), 18–20
weeks (mature; 5 CBA and 7 STR/Ort mice), and 40–42 weeks
(aged; 9 CBA and 14 STR/Ort mice). Left knee tibial and
femoral surfaces were exposed, and AC from each condyle was
isolated using a Friedman-Pearson micro-rongeur (extra-fine
tip, 0.7-mm cup width; Fine Science Tools) (7,13), and samples
were kept in RNAlater (Qiagen). Right knees were processed
for histologic examination.
RNA extraction and microarray process. A sample
of AC from each STR/Ort and CBA mouse (n ⫽ 4 for each
strain at each age) was immersed in QIAzol (Qiagen), homogenized, and total RNA was isolated with a Qiagen Mini Kit.
RNA quality was assessed using an Agilent 2000 Bioanalyzer.
Samples were stored at ⫺80°C. In vitro transcription was
achieved with a BioArray high-yield RNA transcript labeling
kit (Affymetrix). Unincorporated nucleotides were removed
using an RNeasy column (Qiagen). Hybridization to a total of
24 Affymetrix Mouse Gene 1.0 ST Arrays (1 sample per array;
n ⫽ 4 samples per age group for each mouse strain), washing,
staining, and scanning of arrays were performed according
to the manufacturer’s instructions (see array design online at
https://www.affymetrix.com). Standard quality assessment
(housekeeper 5⬘:3⬘ ratios, scaling factors) and individual array
quality were controlled by hierarchical clustering and by NUSE
to identify outliers (2 samples were removed from analyses;
1 sample each from 8-week-old and 40-week-old CBA mice).
Raw data were submitted to the Gene Expression Omnibus
(GEO) database (accession no. GSE33754; online at www.ncbi.
nlm.nih.gov/geo).
Array analysis. Microarray data were normalized using
Robust Mean Analysis and log2-file routines and analyzed in
an R environment using Significance Analysis of Microarrays
(SAM) (http://www-stat.stanford.edu/⬃tibs/SAM/ [14]), which
provides a list of statistically significant genes and an estimate
of the false discovery rate (FDR). SAM analysis calculates
statistically significant genes by determining the percentage of
genes discovered by chance through permutations of repeated
measures from a candidate gene list. This generates a robust
estimation of FDR. A gene list set at an appropriate FDR was
then obtained. Genes were considered significantly changed
when delta values corresponding to the number of false significant genes were ⬍5% (q value) and an average 1.5-fold
change was achieved. A 1.3-fold change was used for comparison to other studies. We used Ingenuity Pathways Analysis
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(IPA; http://www.ingenuity.com) to discover networks regulated by aging and OA vulnerability, onset, or progression.
Only networks with high confidence limits are reported. Gene
lists for each comparison selected by SAM analysis were input
into IPA, Core analysis was run, and Benjamini and Hochberg
test was used to calculate P values for each function (highest
P value found in the category). Array profiles of tissues obtained from the GEO database were used for comparing
muscle gene expression levels (tibialis anterior muscle, accession no. GSE11105; heart, accession no. GSE12420; liver,
accession no. GSE21060; testes, accession no. GSE16853; ovary,
accession no. GSE16853; and duodenum, accession no.
GSE18074).
Real-time quantitative polymerase chain reaction
(qPCR). We used real-time qPCR to measure gene expression
levels in 40-week-old CBA and STR/Ort mice (n ⫽ 6 per
strain). Reverse transcription was performed on 1 g of RNA
(20-l reaction volume) using a high-capacity RNA-to–
complementary DNA (cDNA) kit (Applied Biosystems) run at
37°C for 60 minutes and at 85°C for 5 minutes. To detect
messenger RNA (mRNA) transcripts, primers (Supplementary Table 1, available on the Arthritis & Rheumatism web site
at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)15290131) were premixed with SYBR Green JumpStart Taq
ReadyMix (Sigma-Aldrich), and 10-l aliquots were applied to
384-well optical plates (Bio-Rad). The cDNA was diluted 1:10,
and triplicate 2-l aliquots were added. Thermal cycling conditions were as follows: 10 minutes at 95°C, with 40 cycles of
15 seconds at 95°C, 30 seconds at 62°C, and 20 seconds at 72°C,
on a Bio-Rad CFX384 Real-Time System. The cDNA was
diluted (200⫻), and 18S levels were measured by TaqMan
assay according to the manufacturer’s protocol (Applied Biosystems).
Histologic assessment. Right knees were fixed and
decalcified (Immunocal; Quartett), and coronal wax sections
were cut (15). Serial sections taken at regular 120-m intervals
across the entire joint were stained with toluidine blue, and AC
lesions were scored using a previously described system (15),
and a mean ⫾ SEM grade per joint was calculated. Briefly,
changes in the AC were graded on a scale of 0–6, where 0 ⫽
normal, 1 ⫽ rough AC surface/lesions in superficial zone, 2 ⫽
lesion down to intermediate AC, 3 ⫽ lesions down to tidemark
or loss of AC, 4 ⫽ AC loss across 20–50% of the condylar
surface, 5 ⫽ AC loss across 50–80% of the condylar surface,
and 6 ⫽ loss of AC with exposed subchondral bone. Osteophyte formation was also scored as described previously (16),
using a scale of 0–3, where 0 ⫽ none, 1 ⫽ predominantly
cartilaginous, 2 ⫽ cartilage and bone with chondrocyte hypertrophy and bone formation, and 3 ⫽ predominantly bone with
marrow.
Sections of joints from representative 8-week-old CBA
and STR/Ort mice (n ⫽ 4 per strain) were dewaxed, pepsindigested (3 mg/ml in 0.02M HCl for 45 minutes at 37°C),
blocked with 10% normal goat serum (for 1 hour), and p65
antibodies (recognizing the p65 subunit of NF-B) were applied overnight at 4°C (1:10 dilution; Santa Cruz Biotechnology). After washing, sections were incubated for 1 hour with
biotinylated goat anti-rabbit secondary antibody (1:200 dilution; Dako) and for 30 minutes with a Vectastain elite ABC kit
(Vector). Sections were stained with a diaminobenzidine substrate kit (Vector).
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Flow cytometry. Flow cytometry was performed as
described elsewhere (17). Briefly, a splenic suspension was
prepared by teasing the spleens (n ⫽ 4 per age group per
strain), and the residual erythrocytes were removed by lysis
using 0.85% NH4Cl. Spleen cells were washed in cold phosphate buffered saline (PBS), counted, and incubated with
combinations of fluorochrome-conjugated monoclonal antibodies for 1 hour at 4°C: anti-CD4, anti-CD44, anti-CD62L,
anti-CD86, anti-CD45R (B220), and isotype controls (all from
eBioscience). After 2 washes in PBS, cells were fixed in 1%
paraformaldehyde and analyzed using FACSCanto II instrument (Becton Dickinson). Data were processed using FlowJo
software (Java Software).

RESULTS
Confirmation of validity of known OA targets by
analysis of cartilage in diseased STR/Ort mice. STR/Ort
mice are a well-known spontaneous model of OA. There
was increased severity of AC lesions with age in these
mice, which demonstrated early OA at 18 weeks and
late-stage disease at 40 weeks (Figures 1A–G). In contrast, CBA mice showed only very mild, if any, AC
lesions at 18 weeks and no age-related progression
(Figures 1A–G). In addition, only mild osteophytes were
detected in AC samples from 40-week-old CBA mice
(grade 1 in 4 of 9 mice), whereas STR/Ort mice developed mild osteophytes from 18 weeks (grade 1 in 3 of 7
mice) and had increased maturation scores at 40 weeks
(grade 3 in 6 of 14 mice).
Our main objective was to use microarray analysis to define risk and disease genes and to plot how these
alter with aging. First, we contrasted gene expression
in all nondisease samples (8-week-old STR/Ort and all
CBA mice) with all OA samples (18-week-old and
40-week-old STR/Ort mice). Such merging of data from
the 2 strains effectively limits any differences attributable solely to strain-specific variation, which might be
unrelated to OA, and provides the greatest statistical
power. This analysis revealed 390 up-regulated and 272
down-regulated genes in the OA samples (Supplementary
Table 2, available on the Arthritis & Rheumatism web site
at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)
1529-0131).
A significant number of genes described in a
recent editorial (7,18–22) as being OA targets based
on the results of microarray analysis of human OA
and a rat model were also identified (Figure 1I), providing further confirmation of the relevance of our
preclinical STR/Ort mouse model to human OA.
Among these genes, levels of mRNA for Col2a1, tissue
inhibitor of metalloproteinases 1 (TIMP-1), MMP-13,
and ADAMTS-4 were further investigated by qPCR and
showed increased levels in AC samples from 40-weekold STR/Ort mice as compared to those from age-
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Figure 1. Increased osteoarthritis (OA) severity and expression of selected markers of extracellular matrix (ECM) turnover in STR/Ort mice. A,
Grading of knee joint articular cartilage (AC) lesions in CBA mice and STR/Ort mice at ages 8–10 weeks (n ⫽ 5 or more mice per strain), 18–20
weeks (n ⫽ 5 or more mice per strain), and 40–42 weeks (n ⫽ 9 or more mice per strain) shows increased OA severity in STR/Ort, but not CBA
mice. Values are the mean ⫾ SEM. ⴱⴱ ⫽ P ⬍ 0.01. B–G, Toluidine blue staining of knee joint sections from STR/Ort mice, but not CBA mice,
obtained at ages 8 weeks, 18 weeks, and 40 weeks shows increasing OA severity over time (arrows). H, Levels of mRNA for the ECM turnover
markers COL2A1, tissue inhibitor of metalloproteinases 1 (TIMP-1), matrix metalloproteinase 13 (MMP-13), and ADAMTS-4 show increased
expression in AC samples from STR/Ort mice at 40 weeks of age as compared with samples from CBA mice (n ⫽ 6 mice per strain). I, Genes
demonstrating increased expression in samples of OA cartilage from STR/Ort mice that have also been identified in human OA or animal models
are shown. Their selection was based upon their increased expression in previous array studies (7,18–22). Only selected genes with q values ⬍5%
and a ⬎1.3-fold change are shown. Broken horizontal line in H and I shows mean control levels in CBA mice against which the levels in STR/Ort
mice were corrected. Values in H and I are the ratio of the mean. Color figure can be viewed in the online issue, which is available at
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131.

matched CBA mice (Figure 1H). Bibliometric pathway
analysis (Ingenuity) found that the top molecular or
disease functions associated with these genes included
cancer (P ⫽ 2.45–13), reproductive system diseases (P ⫽
8.43–13), and cell-to-cell interaction and signaling (P ⫽
2.13–12) and that NF-B pathway signaling (see below)
was the most common molecular network upon which all
of these were centered. This comparison revealed that
many of the known OA targets are also differentially
expressed by AC in STR/Ort mice and that these are
centered upon the NF-B pathway.
Gene expression changes related to OA predisposition, onset, and progression. To identify genes that
characterize OA risk, we determined chondrocyte gene
expression prior to OA onset by comparing samples
from 8-week-old STR/Ort mice with those from agematched CBA mice. This analysis showed that 139 genes
were up-regulated and none were down-regulated in
STR/Ort mice relative to CBA mice (Figure 2 and
Supplementary Table 3, available on the Arthritis &

Figure 2. Schematic representation of the number of genes found to
be differentially up-regulated and down-regulated across several comparisons. Numbers are restricted to those showing ⬎1.5 fold differential expression with a q value ⬍5%. Adjustment for additional multiple
testing was not made for secondary comparisons. Our primary comparisons included differential expression between the CBA and the
STR/Ort mouse strains at baseline and comparison of youngest to
oldest age groups (8 weeks versus 40 weeks) between the two strains
(n ⫽ 4 mice per strain, except for CBA mice at 8 weeks and 40 weeks,
which were n ⫽ 3 after quality control was performed).
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Rheumatism web site at http://onlinelibrary.wiley.com/
journal/10.1002/(ISSN)1529-0131). Among those that
were up-regulated, were several ECM genes, including
types VIII and XII collagen, tenascin-C, MMP-19,
HTRA-1, and TIMP-1. Pathway analysis suggested that
their main functions included genetic and connective
tissue disorders (P ⫽ 8.32–06), such as arthritic diseases
and Dupuytren’s contracture, and cell death (P ⫽ 4.19–05).
As found in healthy versus OA samples, pathway
analysis also revealed that the top networks into which
these “risk” genes were centered featured significant
NF-B complex involvement (Figure 3A). The likely
importance of this NF-B pathway was confirmed by
immunohistochemical labeling, which disclosed increased levels of p65 NF-B subunit expression in
chondrocytes from STR/Ort mice as compared to those
from CBA mice (Figures 3B–E). This immunologic/
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inflammatory signature found in STR/Ort mouse chondrocytes before the appearance of overt OA prompted
examination of their immunologic phenotype. These
analyses strengthened this connection by showing that
8-week-old STR/Ort mice had increased spleen cellularity, decreased naive T cell numbers, and increased
activated T cell and B cell numbers (Figures 4A–D);
consistent with heightened inflammatory status prior to
OA onset and modified NF-B pathway signaling as a
potential common molecular etiology for OA and immune phenotypes in STR/Ort mice.
Gene changes associated with OA onset were
defined by comparing AC samples from 8-week-old STR/
Ort mice with those from 18-week-old STR/Ort mice.
This showed 2 up-regulated and 113 down-regulated
genes (Figure 2 and Supplementary Table 4, available on
the Arthritis & Rheumatism web site at http://online

Figure 3. Linkage of osteoarthritis (OA) susceptibility of articular cartilage (AC) in STR/Ort mice to the NF-B complex. A, Network involving the
NF-B interactions (blue) formed by genes that are up-regulated in STR/Ort mice as compared to CBA mice at 8 weeks of age (before OA onset).
Genes up-regulated in STR/Ort mice (pink/red) and other genes (white) are included based on known interactions with the NF-B network. B–E,
Immunohistochemistry for p65 in 8-week-old CBA mice and STR/Ort mice. Levels of p65 protein were increased in AC chondrocytes from STR/Ort
mice. Images in C and E are higher-magnification (⫻20) views of the boxed areas in B and D (⫻10), respectively. Results are representative of 4
mice per group. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131.
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with normal AC aging. Replication of this age-related
change in gene expression in normal human AC is
required before the potential OA relevance is fully
recognized.
Ontology analysis (Ingenuity) and visual inspection revealed that most down-regulated genes in this
category were, surprisingly, skeletal muscle–specific isoforms of various structural, metabolic, and matrixrelated proteins (Table 1); their age-dependent changes

Table 1. Identity of main functional categories linked to genes
differentially expressed in CBA and STR/Ort mice between 8 weeks
and 40 weeks of age*
Category, functional annotation
Figure 4. Increased numbers of total and activated T cells and B cells
in the spleen of STR/Ort mice. At both 18–20 and ⱖ40 weeks of age,
STR/Ort mice (solid bars) show increased splenic cellularity (A),
decreased naive T cell numbers (B), increased activated memory T
cells (C), and increased B cell activation (D) as compared to the CBA
mice of the same age groups (open bars). Values are the mean ⫾ SEM
of 4 mice per group. ⴱ ⫽ P ⬍ 0.05; ⴱⴱ ⫽ P ⬍ 0.01; ⴱⴱⴱ ⫽ P ⬍ 0.001 by
two-way analysis of variance comparing all variables, with Bonferroni
multiple-comparison post-test.

library.wiley.com/journal/10.1002/(ISSN)1529-0131),
none of which had previously been ascribed roles in OA.
Pathway analysis revealed that their top functions included lymphocyte proliferation (P ⫽ 6.96–05) and differentiation and activation (P ⫽ 1.19–04) and that their
top network was again focused on NF-B signaling.
Interestingly, no further changes in AC gene expression
were observed at later stages of OA (18-week-old versus
40-week-old STR/Ort mice) (Figure 2).
Discovery of a myogenic signature in young AC
that is lost during normal aging but not in the presence
of OA. The gene expression profile linked with healthy
AC chondrocyte aging but not with OA has not been
described in mice. Using CBA mice as a model of
healthy AC aging, since they never exhibit overt OA,
we found 190 genes (50 up-regulated and 140 downregulated) that were differentially expressed between
young (8 weeks) and aged (40 weeks) AC from non–
OA-prone CBA mice (Figure 2 and Supplementary
Table 5, available on the Arthritis & Rheumatism web site
at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)
1529-0131). These genes did not include previously defined OA targets, but did include cartilage intermediatelayer protein (CILP) and histone deacetylase 5 (HDAC5), suggesting that deviation in their levels is associated

CBA mice
Skeletal and muscular system development
and function
Contraction of muscle
Contraction of skeletal muscle
Contraction of striated muscle
Development of muscle
Tissue morphology
Contraction of muscle
Contraction of skeletal muscle
Contraction of striated muscle
Skeletal and muscular disorders
Myopathy
Skeletal and muscular disorder
Huntington’s disease
Muscular dystrophy
Duchenne’s muscular dystrophy
STR/Ort mice
Cellular growth and proliferation
Proliferation of blood cells
Proliferation of lymphocytes
Proliferation of B lymphocytes
Proliferation of normal cells
Proliferation of eukaryotic cells
Hematologic system development and
function
Proliferation of lymphocytes
Proliferation of B lymphocytes
Differentiation of B lymphocytes
Quantity of B lymphocytes
Quantity of B-1 lymphocytes
Humoral immune response
Proliferation of B lymphocytes
Differentiation of B lymphocytes
Quantity of B lymphocytes
Quantity of B-1 lymphocytes
Quantity of pre–B lymphocytes

No. of
molecules

P

32
11
9
9

1.43⫺28
8.17⫺13
1.03⫺10
2.33⫺02

32
11
9

1.43⫺28
8.17⫺13
1.03⫺10

16
60
27
7
4

2.48⫺13
1.29⫺11
1.42⫺11
4.32⫺05
1.05⫺03

29
27
15
41
48

2.33⫺06
2.33⫺06
1.78⫺05
1.05⫺04
6.04⫺04

27
15
11
12
6

2.33⫺06
1.78⫺05
1.93⫺04
5.29⫺04
6.37⫺04

15
11
12
6
6

1.79⫺08
4.53⫺07
1.42⫺06
2.77⫺06
3.98⫺06

* Analysis revealed regulation of muscle-specific genes during healthy
aging in only the CBA mice. Genes closely linked to hematopoietic cell
lineage functions were revealed in aging osteoarthritis-prone STR/Ort
mice. Ingenuity Pathway Analysis was used to identify the top 3
categories and their main functional annotations (selection based on
containing ⬎4 molecules and significance at P ⬍ 0.05 after Benjamini
and Hochberg correction). The full list of molecules associated
with these functions is given in Supplementary Table 7, available on
the Arthritis & Rheumatism web site at http://onlinelibrary.wiley.com/
journal/10.1002/(ISSN)1529-0131.
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Figure 5. Muscle-specific gene expression in articular cartilage (AC)
samples from CBA mice and STR/Ort mice over time. A, Myogenic
gene profiling disclosed decreases in expression in CBA mice, but not
STR/Ort mice with age (n ⫽ 4 mice per group; 42 probe sets). B, Ratio
of mRNA expression of myosin heavy chain 1 (Myh1) and myogenic
factor 6 (Myf6), as determined by quantitative polymerase chain
reaction techniques, in AC samples at 40 weeks of age relative to 8
weeks of age confirmed decreases in the CBA mice, but not the
STR/Ort mice (n ⫽ 3 mice per group). C, Microarray-derived gene
profiles of the “skeletal muscle” signature in cartilage more closely
resembles murine skeletal muscle (Tib), than heart, liver, testes, ovary,
or colon (Duo) (n ⫽ 3 mice per group, except for ovary, which was 2
mice per group). Data are shown as box plots. Each box represents the
25th to 75th percentiles. Lines inside the boxes represent the median.
Lines outside the boxes represent the 10th and the 90th percentiles.
Circles indicate outliers.
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in expression are plotted in Figure 5A. Two features
are striking. First, their level of expression in AC samples from CBA mice was higher than in samples from
STR/Ort mice. Second, the muscle “program” is
switched off, at least in part, in aged CBA mice, but not
STR/Ort mice (Figure 5A), which retain AC expression throughout the aging/disease process. These agingrelated patterns of muscle-specific gene expression were
indeed confirmed by qPCR for myogenic factor 6 and
myosin heavy chain 1 (Figure 5B). Pathway analysis of
the genes differentially regulated between 8 weeks and
40 weeks in AC samples from STR/Ort mice revealed
their relatedness to cellular growth and proliferation
and to lymphocyte development and function (Table 1
and Supplementary Table 6, available on the Arthritis &
Rheumatism web site at http://onlinelibrary.wiley.com/
journal/10.1002/(ISSN)1529-0131). It is most critical to
note that the expression of these muscle-specific genes is
not ubiquitous and that their expression is higher in AC
than in heart muscle and is remarkably close to that
found in adult murine skeletal muscle (higher than in
liver and testes) (Figure 5C). Our data also showed
that AC retained some aspect of the muscle gene
expression program throughout life at a remarkably high
level of expression (Supplementary Figure 1, available
on the Arthritis & Rheumatism web site at http://online
library.wiley.com/journal/10.1002/(ISSN)1529-0131).
Using IPA, 13 of the nonmuscle genes that were
down-regulated in both CBA and STR/Ort mice between 8 weeks and 40 weeks of age, which are most likely
related to non-OA healthy aging, were found to serve
known roles in hematologic disorders and function (P ⫽
6.67–05). It is possible that genes found only in the AC of
STR/Ort mice are specifically linked to the OA that
occurs at these ages and include 43 up-regulated and
209 down-regulated genes that are unmodified in CBA
mice between 8 and 40 weeks of age. These genes are
involved in the inflammatory response (P ⫽ 2.94–12), cell
death (P ⫽ 6.45–09), and cell growth and proliferation
(P ⫽ 1.13–0.7) pathways, all of which are centered on
NF-B signaling. Unusually, none had previously identified links with OA development.
These findings indicate that AC from normal, but
not OA, mice has a myogenic signature in the young that
diminishes in its expression during healthy aging AC
and that NF-B pathway signaling might act as a hub in
driving gene expression changes in OA-prone mice.
DISCUSSION
In this study, we used a model of natural, spontaneous OA in STR/Ort mice as compared to age-
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matched non–OA-prone CBA mice to determine the
AC gene expression profiles specific to OA susceptibility, early and late-stage disease, and healthy aging. We
found that AC from STR/Ort mice with overt OA
displays an expression profile consistent with that previously described in human OA and in animal models of
OA (including types II and X collagen, MMP-3, and
TIMPs 1–3), confirming these mice as a valuable model
of disease pathology. This study also showed that chondrocytes had a strong myogenic signature that was
partially down-regulated with age in healthy AC, but
was retained or reexpressed in aging OA cartilage from
STR/Ort mice. We found that chondrocytes also possess
an inherent inflammatory gene phenotype involving the
NF-B pathway, which is likely linked to early OA in
these mice, and that early and late OA profiles implicate
similar processes. This study therefore confirms several
known targets by use of a spontaneous murine model of
OA, defines new targets, including those converging
upon NF-B pathway signaling, and defines a myogenic
program, which may be used to monitor, attenuate, or
even treat OA.
STR/Ort mice develop OA spontaneously and
are a model of natural (primary) OA (9–11,23–29).
Their OA develops relatively predictably, with first signs
presenting at 18 weeks of age and progressing toward
loss of AC and exposure of subchondral bone at 40
weeks. Comparison of diseased AC (from STR/Ort mice
at 18 and 40 weeks of age) with AC lacking overt
features of OA (from CBA mice of all ages and from
STR/Ort mice at 8 weeks of age) revealed almost all
changes found in previous arrays using samples from
animal models and humans with OA (7,18–22). This
supports the suitability of STR/Ort mice as a model of
chondrocyte involvement in OA-related AC pathology.
Our analyses also revealed several unexplored or novel
processes that may represent targets for therapeutic
evaluation of OA development.
Watters et al (30) performed microarray analysis of OA joints from STR/Ort mice using matched
tissue from younger STR/Ort mice, thus removing any
chance of detecting age-related gene changes or differences based on genetic background. They described
changes associated with osteophyte development that
correlated with AC lesion severity and found peroxisome proliferator–activated receptor ␥ (PPAR␥) and
PPAR␣ to be central to OA in STR/Ort mice. However,
by not including AC samples from non–OA-prone mice,
their analysis did not specifically identify the muscle
expression program noted herein. In our study, we found
that NF-B likely played a central role in OA. Indeed,
NF-B was the top network with regard to diseased
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versus nondiseased joints, OA predisposition in 8-weekold CBA mice versus STR/Ort mice, and during early
OA and late OA. The divergence in the outcomes
between these studies could also rely on the fact that
Watters et al used samples containing both AC and
bone, whereas our samples were limited to AC alone (7).
These data suggest that the role of these
PPARs might be relatively restricted to bone; however,
it should be noted that cartilage-specific PPAR signaling is emerging as an OA target (31,32) and that, like
NF-B, it also integrates into inflammatory signaling
and regulates NF-B function in various tissues (33,34).
It is possible, therefore, that the informatics methods
applied to the identification of transcription signatures
and the timing of these analyses during OA development
underpin the differences seen in their outcomes.
Cytokine signaling has also been associated with
severe OA in humans (18), confirming the potential
modulation of the NF-B signaling pathway as a therapeutic target. This has also been recently discussed in
various review articles (35,36), and inhibition of NF-B
p65 expression was shown to decrease OA development
in a rat surgical model (37). The NF-B network can be
activated by various cytokines, by degradation products
of ECM components such as fibronectin (38,39), and by
mechanical stimuli (40), all of which are increased in
STR/Ort mice during OA (24,25,41). NF-B activation
also plays a role in chondrocyte hypertrophy (42),
which is increased in OA and, consequently, may lead
to MMP and cytokine expression. Levels of MMP and
cytokine expression were also found to be increased in
our study and are known to further increase ECM
degradation, thus contributing to OA progression. The
increased splenic weight and numbers of activated immune cells found in young STR/Ort mice also supports a
general non–tissue-specific proinflammatory state that
may reflect the genetic etiology underpinning OA susceptibility in these particular mice.
It is also pertinent to consider whether these
signatures are causally connected via NF-B or whether
they are separate products with a common molecular
etiology. Clarifying these relationships is crucial, as this
may reveal alternative strategies for OA prevention or
treatment. Nevertheless, it is important to note that OA
in STR/Ort mouse joints occurs without overt inflammation or cell infiltration (11). Modulating NF-B
would also have to be achieved in a cell-specific or tissuespecific manner due to its role in immune and other
skeletal processes. However, given the potential to directly target large OA surfaces with intraarticular injections, proof-of-concept studies are plausible.
It has previously been proposed that early and
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late OA exploit different molecular processes. Indeed,
although the total numbers of differentially regulated
genes were few (14 in total), microarray studies have
shown that chondrocyte gene profiles differ in mild and
severe OA in humans (18). In contrast, our study showed
no difference in gene expression in early and late OA
occurring in STR/Ort mice, which suggests that progression is linear in this spontaneous model and implies that
baseline AC gene signatures may be especially important. The discrepancy with human data may be explained
by distinct classification criteria: early OA in humans
might represent fibrillation without AC loss, whereas
mild AC loss is seen in early OA in mice. Alternatively,
it may point to the need for larger sample sizes for such
studies if they are to detect these discrete processes.
CBA mice have been used as controls for the
STR/Ort strain for decades, as they do not develop overt
OA (9). Indeed, very mild AC lesions occur only rarely
in CBA joints and often fail to advance significantly with
age. This underpins their selection as an appropriate
model of healthy AC. We found that changes in gene
expression in CBA mouse AC were limited and, again,
rather gradual over time. In fact, most genes, except for
CILP, that have been implicated in OA did not change
significantly with age in CBA mice, which bolsters the
likelihood that the OA gene changes we describe are
specific to OA and are unrelated to aging alone. These
analyses also revealed a new chondrocyte signature that
integrated many skeletal muscle gene isoforms, which is
usually associated with contractile cells. This signature
was surprisingly enriched in the AC as compared with
other tissues, was highly expressed in young AC, and
showed age-related declines. This age-related decline in
myogenic gene expression was not, however, evident
in OA chondrocytes from aged STR/Ort mice, in which
this arguably inappropriate signature was retained or
reexpressed. Whether this signature signals an attempt
to repair AC damage or whether it contributes to OA
development in skeletally mature mice is unknown.
During the time we were preparing the manuscript describing our study, Loeser et al (43) reported
that a change in muscle-specific gene expression was
among the genes that were selectively regulated in older,
but not young, mice subjected to surgical destabilization
of the medial meniscus. Although the lack of any solely
age-related decline in muscle-specific gene expression
in those studies may be due to their inclusion of non-AC
tissues (43), their findings support a role for a muscle
signature in OA. The role of this program clearly requires further interrogation.
The presence of myogenic gene expression in
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young chondrocytes most likely relates to their common
origin with muscle cells during development, yet it is
very surprising to observe high absolute levels of expression in nonmuscle tissue into adulthood. Indeed, while
chondrocytes, brown fat cells, and myocytes are formed
from mesoderm-derived mesenchymal stem cells (44–
46), the myogenic isoforms of contractile, ECM, and
energy metabolism were not thought to be found in
mature tissues not containing striated muscle. Appearance of this program in OA chondrocytes might indicate
that they exhibit some dedifferentiation and is consistent
with a reexpression of type IIA collagen (47) and an
increase in mesenchymal progenitor cells (48) in OA
joints. The findings therefore further extend the repertoire of factors reflecting recapitulation of developmental mechanisms in OA (49).
As with other microarray studies in animal models, some caveats remain. First, OA in STR/Ort mice
does not rely on external induction and may thus show
greater variability even within this inbred population.
This is similar to any studies with human OA cartilage,
but it adds further complexity and increases the scope
for assessing the genes involved. Second, the appropriateness of using CBA mice as a control strain is questionable. This choice makes our study consistent with
previous work and is based on their relatively low
incidence of age-related OA. The CBA mouse is also the
commercially available strain that is most closely related
to the STR/Ort strain (50), and its use in this study
attempts to additionally adjust for age-related changes.
Care should be taken when comparing different strains,
as this may exaggerate differences in gene expression
that may be unrelated to disease status. Third, use of
40-week-old mice as representative of “aged” AC is
debatable. Until aging is more completely understood,
however, many factors, including chronology, relationship to skeletal or sexual maturation, or even total likely
lifespan, may affect the interpretation of these data. We
chose 40 weeks since at this age, AC is still available in
adequate quantities from the OA joints of STR/Ort
mice.
In conclusion, we found that NF-B signaling is
central to the gene changes that take place in AC
chondrocytes during natural OA development in STR/
Ort mice. Our studies also revealed a new chondrocyte
gene expression signature in which muscle-related genes
are down-regulated with normal aging, but stay highly
expressed in OA. This study highlights these two pathways as possible targets for slowing OA progression in
nontraumatic, natural OA, as well as possible markers of
disease status.
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